Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ER2001 in early manifest Huntington's disease
NCT07339514Phase 2Active, not recruiting
- Sponsor
- ExoRNA Bioscience
- Start
- Feb 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of ER2001 in Huntington's disease (HD), sponsored by ExoRNA Bioscience. Started Feb 2025; status: active, not recruiting.
02
Drugs
ER2001
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT07339514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339514.